NOVA ACQUIRES RIGHTS TO BRADYKININ ANTAGONISTS
NOVA ACQUIRES RIGHTS TO BRADYKININ ANTAGONISTS under an exclusive worldwide agreement with two University of Colorado scientists, John Stewart and Raymond Vavrek, the company announced in a May 7 press release. Nova said the compounds "block the activity of bradykinin, one of the body's natural causes of pain and inflammation." Terms of the agreement were not disclosed. Nova explained that bradykinin "is a small protein molecule, or peptide, produced in blood plasma during certain pathologic situations. It is involved in many inflammatory conditions, including arthritis, colds, shock, and the pain and inflammation of wounds, burns and cuts." The firm said the substance "is believed to produce its effects by directly acting on specific receptors in sensory nerves to cause pain, and by stimulating the production of prostaglandins and leukotrienes." Nova President Donald Stark said that "if the required animal and human testing for safety and efficacy prove successful, the first commercial use of bradykinin antagonists is expected to be in topical applications for pain control directly on wounds." The firm told "The Pink Sheet" that it hopes to file an NDA in two years. An IND has not yet been filed. The release stated that "according to Stewart and Vavrek, the major drugs currently used for inflammation, including steroids and such nonsteroidal anti-inflammatory drugs as aspirin and ibuprofen, inhibit the production of prostaglandins, which are molecules responsible for inflammatory processes." Nova said "since bradykinin stimulates the production of prostaglandins in the tissues, scientists expect bradykinin antagonists to block prostaglandin production as well as interfere directly with bradykinin's pain-producing properties."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: